Crossmark

miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway

Published Online: 2019-09-30

Published Print: 2019-12

Authors

Zheng, Tian-Liang

Li, De-Ping

He, Zhan-Feng

Zhao, Song http://orcid.org/0000-0002-7831-1314
License Information

Text and Data Mining valid from 2019-09-30

Version of Record valid from 2019-09-30
More Information

Article History

Received: 28 May 2019

Accepted: 18 August 2019

First Online: 30 September 2019

Ethics approval and consent to participate

: The study protocol was designed and approved by the ethical committee of the First Affiliated Hospital of Zhengzhou University.

: Informed consent was obtained from all patients.

: The authors declare that they have no competing interests.

Document is current